{"disease":{"id":"epstein-barr-virus-associated-hodgkin-s-lymphoma","name":"epstein barr virus associated hodgkin s lymphoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05011058","title":"An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":102,"lead_sponsor_name":"Viracta Therapeutics, Inc.","has_results":true},{"nct_id":"NCT01805037","title":"Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":20,"lead_sponsor_name":"Northwestern University","has_results":true},{"nct_id":"NCT01964755","title":"Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"University of Miami","has_results":true}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}